In vivo characterization of white matter pathology in pre‐manifest Huntington's disease by Zhang, J et al.
RESEARCH ARTICLE
In Vivo Characterization of White Matter
Pathology in Premanifest Huntington’s
Disease
Jiaying Zhang, MPhil,1 Sarah Gregory, PhD,2,3 Rachael I. Scahill, PhD,2,4
Alexandra Durr, MD, PhD,5 David L. Thomas, PhD,6,7 Stéphane Lehericy, MD, PhD,8
Geraint Rees, PhD,3 Sarah J. Tabrizi, MD, PhD,2,3 and Hui Zhang, PhD,1
the TrackOn-HD investigators
Objective: Huntington’s disease (HD) is a monogenic, fully penetrant neurodegenerative disorder, providing an ideal
model for understanding brain changes occurring in the years prior to disease onset. Diffusion tensor imaging (DTI)
studies show widespread white matter disorganization in the early premanifest stages (pre-HD). However, although DTI
has proved informative, it provides only limited information about underlying changes in tissue properties. Neurite ori-
entation dispersion and density imaging (NODDI) is a novel magnetic resonance imaging (MRI) technique for character-
izing axonal pathology more speciﬁcally, providing metrics that separately quantify axonal density and axonal
organization. Here, we provide the ﬁrst in vivo characterization of white matter pathology in pre-HD using NODDI.
Methods: Diffusion-weighted MRI data that support DTI and NODDI were acquired from 38 pre-HD and 45 control
participants. Using whole-brain and region-of-interest analyses, NODDI metrics were compared between groups and
correlated with clinical scores of disease progression. Whole-brain changes in DTI metrics were also examined.
Results: The pre-HD group displayed widespread reductions in axonal density compared with control participants; this
correlated with measures of clinical disease progression in the body and genu of the corpus callosum. There was also
evidence in the pre-HD group of increased coherence of axonal packing in the white matter surrounding the basal
ganglia.
Interpretation: Our ﬁndings suggest that reduced axonal density is one of the major factors underlying white matter
pathology in pre-HD, coupled with altered local organization in areas surrounding the basal ganglia. NODDI metrics
show promise in providing more speciﬁc information about the biological processes underlying HD and neurodegen-
eration per se.
ANN NEUROL 2018;84:497–504
Characterizing brain changes that occur in neurodegen-eration prior to symptom onset can provide targets
for interventions that may delay or completely arrest the
progression of disease.1 Huntington’s disease (HD) is a
monogenic, neurodegenerative disorder, characterized by
motor, cognitive, and neuropsychiatric disturbance.2 As it
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is both autosomal dominant and fully penetrant, HD gene
carriers can be identiﬁed many years prior to clinical
onset, enabling neurodegenerative brain changes to be
tracked from the earliest stages.
Structural magnetic resonance imaging (MRI) stud-
ies have shown robust white matter degeneration in pre-
manifest HD (pre-HD).3–5 Neuronal loss initially affects
the striatum, but this is followed by reductions in white
matter surrounding the basal ganglia, which extend to cor-
tical white matter throughout the cortex. To understand
further the nature of these macrostructural changes, it is
necessary to investigate underlying alterations in the tissue
properties of white matter. This is possible in vivo using
diffusion tensor imaging (DTI),6 which provides an indi-
rect assessment of white matter microstructure. DTI stud-
ies in HD have shown widespread abnormalities in white
matter tissue microstructure in pre-HD gene carriers, with
evidence of a widespread reduction in fractional anisotropy
(FA; a measure of water diffusion in the direction of the
main underlying pathway) and mean diffusivity (MD) in
a series of white matter pathways and regions including
the corpus callosum, motor regions, and frontal tracts,
indicating increased white matter disorganization.7–11 It
has been suggested that these changes represent axonal
degeneration. Animal models of HD, for example, show
that mutant huntingtin impairs axonal transport.12,13
However, this has yet to be directly observed in vivo in
humans, and although the changes observed using DTI
are consistent with underlying axonal degeneration in
HD, they can also be explained by other microstructural
alterations, such as increases in water content.
Recent progress in quantitative MRI has introduced
new techniques that can be used to achieve more direct
in vivo characterization of white matter microstructure
including the potential role of axonal pathology. Neurite
orientation dispersion and density imaging (NODDI), for
example, applies a 3-compartment tissue model to multi-
shell diffusion-weighted imaging (DWI) data, which
allows the interrogation of both intra- and extracellular
properties of white matter tissue and in turn enables dif-
ferentiation of 2 key aspects of axonal pathology: the
packing density of axons in white matter (neurite density
index [NDI]) and the spatial organization of the axons
(orientation dispersion index [ODI]).14 The amount of
free water present (free water fraction) is also indepen-
dently quantiﬁed. Using this approach, changes in axonal
density can be distinguished from those in axonal spatial
organization, while removing the potentially confounding
effect of free water, which increases in areas of tissue
degeneration.15
In the current study, we used NODDI to character-
ize in vivo white matter pathology during the premanifest
stage of HD in a cross-sectional cohort of 38 pre-HD
gene carriers and 45 controls from the multisite Track-On
HD study.16 Using whole-brain analysis, tract-based spa-
tial statistics (TBSS),17 we examined differences in
NODDI metrics (NDI and ODI) between controls and
pre-HD gene carriers in addition to standard DTI metrics
(FA and MD) plus axial diffusivity (AD) and radial diffu-
sivity (RD). We then correlated clinical markers of disease
progression with NODDI metrics extracted from a set of
empirically derived white matter regions of interest (ROIs).
We predicted that axonal density reduction would be the
main feature of white matter pathology and would correlate
with clinical markers of disease progression in pre-HD.
Subjects and Methods
Participants
Forty pre-HD gene carriers and 52 controls were recruited at
2 sites (Paris and London) for the ﬁnal visit of the Track-On
HD study. Pre-HD participants were required to have a
cytosine–adenine–guanine (CAG) repeat length ≥ 40 and a dis-
ease burden score18 > 250 at recruitment. Cumulative probabil-
ity to onset (CPO)19 and Uniﬁed Huntington’s Disease Rating
Scale (UHDRS) total motor score (TMS)20 were also used as
clinical measures of disease progression.
Both these measures aim to estimate disease severity, with
CPO representing the calculated distance from onset based on
age and number of CAG repeats; TMS is an empirical clinical
measure of motor function. Initial recruitment into the Track-
On HD study excluded those with manifest disease, age < 18
or > 65 (unless previously in the Track-On HD study), major
psychiatric, neurological, or medical disorders, or a history of
severe head injury; for full details see Klöppel et al.16 The study
was approved by the local ethics committees, and all participants
gave written informed consent according to the Declaration of
Helsinki.
MRI Acquisition
Multi-shell DWI data were acquired for NODDI analysis, and
single-shell DWI data were acquired for standard DTI analysis at
both sites using 3T MRI scanners (Tim Trio, Siemens Healthcare,
Erlangen, Germany). A twice-refocused spin-echo echo-planar imag-
ing sequence was used to minimize the eddy-current distortion for
both acquisitions. The multi-shell protocol for NODDI consisted
of b values of 2,000, 700, and 300s/mm2 with 64, 32, and 8 non-
linear diffusion-encoding directions, respectively; 14 b = 0s/mm2
images; voxel size = 2.5 × 2.5 × 2.5mm3; repetition time
(TR) = 7,000 milliseconds; echo time (TE) = 90.8 milliseconds;
55 slices; acquisition time = 15 minutes. The single-shell protocol
for DTI consisted of a single b value of 1,000s/mm2 and 42 non-
linear diffusion-encoding directions; 7 b = 0s/mm2 images; voxel
size = 2 × 2 × 2mm3; TR = 13,100 milliseconds; TE = 88 milli-
seconds; 75 slices; acquisition time = 9.5 minutes.
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MRI Data Analysis
Both single- and multi-shell data were initially visually inspected
for coverage, motion, and/or ghosting artifacts and to verify min-
imal eddy-current distortions. Following motion correction,21
NODDI metrics including NDI and ODI were estimated from
the multi-shell data using the NODDI MATLAB toolbox
(http://nitrc.org/projects/noddi_toolbox), and DTI metrics
including FA, MD, RD, and AD were estimated from the
single-shell data using FSL (https://www.fmrib.ox.ac.uk/fsl).22
Individual NODDI and DTI metric maps were then spatially
normalized to the group-speciﬁc template for subsequent TBSS
and ROI analyses using DTI-TK (http://dti-tk.sf.net),23 a state-
of-the-art approach that has been successfully applied to studying
white matter in other neurodegenerative diseases.24,25
Independent 2-sample t tests were performed in FSL to
compare whole-brain NODDI and DTI metrics between pre-
HD and control groups using permutation testing (n = 5,000)
and threshold-free cluster enhancement26 to improve cluster
inference, corrected at p < 0.05. Age, gender, and site were
included as covariates.
ROI analysis was then performed for a set of key white
matter tracts chosen a priori according to the literature.7,8,11,27
The ROIs included the corpus callosum (genu, body, splenium),
the internal capsules (anterior and posterior limbs), and the
external capsules (bilateral internal/external capsules were ana-
lyzed jointly to increase the statistical power). To minimize par-
tial volume effects, ROIs were deﬁned by thinning masks from
the ICBM-81 white matter atlas28 by 1mm. Between-group
comparisons of NODDI metrics for the control and pre-HD
groups were ﬁrst performed using the general linear model, with
age, gender, and site as covariates. The results were false discov-
ery rate–corrected at p < 0.05. For ROIs in which signiﬁcant
group differences were identiﬁed, the extracted NODDI metrics
were correlated with clinical scores of disease progression (CPO
and UHDRS-TMS) corrected at p < 0.05.
Results
Demographic and Clinical Characteristics
Demographic and clinical information is summarized in
Table 1. The pre-HD and control groups were matched for
gender and participation at each site; the average age of the
pre-HD group was lower than that of the control group.
Whole-Brain Analysis
Whole-brain analysis of the NODDI data showed wide-
spread reduced NDI in pre-HD gene carriers when com-
pared with controls (Fig 1A). Reduced NDI was evident
in the corpus callosum, the bilateral superior longitudinal
fasciculi, the posterior limb of internal capsules, the exter-
nal capsules, the posterior thalamic radiations, the middle
cerebellar peduncles, the corona radiata, the uncinate fas-
ciculi, and the posterior cingulum. ODI was also reduced
in more localized regions including the white matter sur-
rounding the basal ganglia, the anterior limb of the
internal capsules bilaterally, the external capsules, and the
right retrolenticular part of internal capsules (see Fig 1B).
Whole-brain analysis of the DTI data showed wide-
spread increased MD in the pre-HD group when compared
with controls in the corpus callosum, the bilateral superior
longitudinal fasciculi, the posterior limb of the internal cap-
sules, the external capsules, the posterior thalamic radiations,
the middle cerebellar peduncles, the corona radiata, the
uncinate fasciculi, and the posterior cingulum (Fig 2A). This
was coupled with reduced FA mainly in the corpus callo-
sum, the superior longitudinal fasciculi, and the posterior
corona radiata bilaterally (Fig 2B). Complementary to the
MD ﬁndings, AD and RD both showed widespread
increases in the pre-HD group compared to the controls.
We found increased AD in the corpus callosum, external
capsules, right cerebellar peduncle, posterior thalamic radia-
tions, corona radiata, and right uncinate fasciculus Fig 2C,
plus increased RD in the corpus callosum, bilateral superior
longitudinal fasciculi, corona radiata, left posterior limb of
internal capsule, left uncinate fasciculus, and left middle cer-
ebellar peduncle Fig 2D.
ROI Analysis
In line with the whole-brain ﬁndings, ROI analyses also
showed a reduction in NDI in the splenium, body and
TABLE 1. Demographic and Clinical Information
Characteristic Control Pre-HD p
n 45 38 N/A
Age, yr,
mean ± SD
(range)
49.1 ± 10.8
(28–69)
44.3 ± 8.6
(28–70)
0.03
Gender, F/M 27/18 17/21 n.s.
Site, London/
Paris
20/25 18/20 n.s.
CAG repeats,
mean ± SD
(range)
N/A 42.9 ± 1.9
(40–47)
N/A
CPO,
mean ± SD
(range)
N/A 0.30 ± 0.18
(0.06–0.75)
N/A
TMS,
mean ± SD
(range)
N/A 6.40 ± 3.85
(0–15)
N/A
CAG = cytosine–adenine–guanine; CPO = cumulative probability to
onset; F = female; M = male; n.s. = not signiﬁcant; N/A = not appli-
cable; Pre-HD = premanifest Huntington’s disease; SD = standard
deviation; TMS = total motor score.
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genu of the corpus callosum, and posterior limb of the
internal and external capsules and decreased ODI in the
anterior limb of the internal capsules in the pre-HD group
compared with controls (Table 2).
NODDI Metric Correlation with Clinical Markers
of Disease Progression
Both CPO and TMS were negatively correlated with NDI
in the body and splenium of the corpus callosum (Fig 3);
that is, reduced density was associated with increasing dis-
ease severity. ODI in the anterior limb of the internal cap-
sules did not correlate with any clinical scores.
Discussion
Using a pre-HD cohort, we have provided the ﬁrst
detailed human in vivo characterization of white matter
axonal pathology in presymptomatic neurodegeneration
with multishell DWI. Using NODDI, a novel technique
for analyzing multishell DWI data, we have shown a wide-
spread reduction in axonal density (indexed by NDI) in
tracts including the corpus callosum and those surround-
ing the basal ganglia in pre-HD. Furthermore, axonal den-
sity reductions in callosal regions predicted clinical
markers of disease progression. These ﬁndings support the
view that axonal pathology is a major factor underlying
white matter degeneration in pre-HD. Interestingly, we
have also shown that the coherence of axonal organization
increased in those tracts surrounding the basal ganglia and
in the internal and external capsules compared to controls.
This suggests possible compensatory pruning of axons in
white matter regions most likely affected in HD. Axonal
pathology may be shared across other neurodegenerative
disorders, and so our ﬁndings potentially offer new mech-
anistic insights into these diseases.
Widespread decreases in axonal density suggest a
proliferation of impaired white matter or anatomical con-
nections between gray matter brain regions in pre-HD
gene carriers, including the anterior and posterior limbs of
the internal capsule, which connect anatomical structures
within the striatum, and the striatum to both the cortex
and the thalamus. These pathways are likely to be affected
in HD, as the striatum is the target of the earliest neuro-
nal loss. These NODDI ﬁndings are further supported by
our independent DTI analysis, where we characterized
whole-brain changes in both FA and MD. Here, we also
observed widespread MD increases in a set of tracts that
overlap with those displaying axon density reductions,
including the corpus callosum, and internal and external
capsules. Although we cannot compare these 2 sets of
ﬁndings statistically and so must proceed with caution,
the NODDI and DTI analyses combined do suggest that
the widespread increased diffusivity in pre-HD can in
principle be explained by reductions in the number of
axons within the ﬁbers of white matter pathways. This is
highly compatible with the evidence of axonal degenera-
tion in animal studies of pre-HD.12,13 It should be noted,
however, that although it is biologically plausible that
reduced NDI is underscored by changes in axonal density,
there may also be an effect of myelin loss. Demyelinated
regions may have a reduced MRI signal and be repre-
sented as reduced NDI by the NODDI model.29
Despite reductions in axonal density being wide-
spread, they were coupled with localized increases in the
directional coherence of axonal organization (as indexed by
a decrease in ODI, ie, a reﬁning of the complexity of the
pathways) in the white matter surrounding the striatum
and in the pathway linking the striatum and thalamus.
These decreases in ODI suggest a process of reorganization
FIGURE 1: White matter abnormalities: neurite orientation dispersion and density imaging (NODDI) analysis. The regional
distribution of differences in NODDI parameters in premanifest Huntington’s disease (pre-HD) gene carriers compared to
controls (NC) is shown. There were reductions in neurite density (neurite density index [NDI]) across the whole brain, indicating a
reduction in axonal density (A), as well as localized reductions in the dispersion of ﬁbers (orientation dispersion index [ODI]) in
the corpus callosum and the internal and external capsule, indicating select pruning of white matter ﬁbers (B), Threshold-free
cluster enhancement (TFCE) p < 0.05. Group differences in NODDI metrics are overlaid on white matter skeleton. [Color ﬁgure
can be viewed at wileyonlinelibrary.com]
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or selective pruning of ﬁbers within tracts linking the stria-
tum to the cortex, potentially compensating for the reduced
axonal density in the same region; this would, however,
require further investigation using a more explicit model of
compensation.30 A recent histological investigation in
patients with multiple sclerosis (MS) using NODDI shows
that ODI is also reduced in MS; a ﬁnding that was con-
ﬁrmed by histology.29 This study showed that in areas of
intense spinal cord demyelination, orientation variability
was reduced, consistent with the existing literature, and that
increased organization may reﬂect pathologically driven
reduced collateral branching or morphological alterations of
individual axons. Together with this evidence, our current
ﬁndings collectively support a unique and more complete
picture of axonal pathology in pre-HD.
Understanding axonal pathology in the early stages of
HD could be central to developing effective therapies for use
in other neurodegenerative diseases, such as Alzheimer’s dis-
ease and Parkinson disease. As the underlying axonal pathol-
ogy associated with the onset of neurodegeneration emerges
many years before clinical symptoms, this may be the opti-
mal point at which to administer therapeutic interventions
that may delay or even prevent clinical onset. Animal models
and postmortem studies are commonly used for studying
disease-related pathology, but both approaches are limited in
tracking disease progression and the relationship between
structure and function. Due to the low prevalence of HD in
the population, this study has used a cross-sectional approach
to examine microstructural change and axonal pathology in a
large group of well-characterized participants with sufﬁcient
variability in their clinical presentation of HD symptoms.
Given that only one time point has been investigated, it is
possible that our ﬁndings simply represent abnormal devel-
opmental change related to the HD gene rather than neuro-
degenerative effects, and despite the lack of empirical
evidence regarding the role of developmental abnormality,
this possibility should be considered. However, we have
shown that it is possible to differentiate alterations to axonal
density from other potential confounding sources, including
axonal spatial organization and free water contamination, in
FIGURE 2: White matter abnormalities: diffusion tensor imaging (DTI) analysis. The regional distribution of differences in DTI
metrics in premanifest Huntington’s disease (pre-HD) gene carriers compared to controls (NC) is shown. There were increases in
mean diffusivity (MD) across the whole brain (A), localized decreases in fractional anisotropy (FA; B), increases in axial diffusivity
(AD) across the whole brain (C), and increases in radial diffusivity (RD) across the whole brain (D), TFCE p<0.05. Group
differences of DTI metrics are overlaid on white matter skeleton. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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pre-HD, which may contribute to linking ex vivo histopath-
ological observations to modern neuroimaging ﬁndings. Fur-
ther investigation in a longitudinal cohort will help to clarify
the mechanistic underpinnings of these alterations.
In terms of limitations, we have used data from
2 research centers to achieve sufﬁcient statistical power
given the relatively low HD prevalence; this can give rise to
potential between-site effects from a number of sources. To
minimize these potential confounding between-site effects,
we used identical acquisition protocols at both sites with
the same scanner model, calibrated with a phantom, and
included site as a covariate in all statistical analyses. Cross-
ing ﬁbers are not explicitly modeled within the NODDI
model; ODI is sensitive to the presence of crossing ﬁbers
and in the case where 2 bundles of ﬁbers cross with only
1 degenerating, reduced ODI will result.31 Furthermore, it
should be noted that NODDI uses a relatively simple com-
partmental model and therefore cannot fully characterize
ongoing pathology. However, it still provides a unique
opportunity to investigate axonal pathology at the micro-
scopic level, both in vivo and noninvasively. As HD is a
disease characterized by movement disorders, it is important
to evaluate the potential impact of motion on our ﬁndings.
We therefore computed the translational motion and rota-
tional motion based on the transformation matrix estimated
for motion correction. We found that there were no signiﬁ-
cant group differences for either the translational motion
(t = −1.733, p > 0.05, df = 81) or the rotational motion
(t = −0.285, p > 0.05, df = 81), and as such we do not
expect motion to have a signiﬁcant impact on the results of
our group analysis. In addition, neither translational not
rotational motion correlated with the CPO measure
(p > 0.05). However, there was an association between
translational motion and NDI (r = −0.272, p < 0.05).
Accordingly, we reanalyzed the correlation between TMS
and NDI extracted from the splenium of the corpus callo-
sum, including translational motion as a covariate, and
TABLE 2. Neurite Orientation Dispersion and
Density Imaging Metrics for the ROI Analysis - NDI
and ODI
WM ROIs
NDI, Mean ± SD
Pre-HD Control p
Genu of corpus
callosum
0.53 ± 0.05 0.56 ± 0.04 <0.001
Body of corpus
callosum
0.58 ± 0.05 0.60 ± 0.04 0.026
Splenium of
corpus callosum
0.60 ± 0.04 0.63 ± 0.03 <0.001
Posterior limb of
internal capsule
0.68 ± 0.05 0.70 ± 0.04 0.023
External capsule 0.50 ± 0.03 0.51 ± 0.02 0.014
ODI, Mean ± SD
Pre-HD Control p
Anterior limb of
internal capsule
0.17 ± 0.01 0.18 ± 0.01 <0.001
False discovery rate (FDR)–corrected, p < 0.05.
NDI = neurite density index; ODI = orientation dispersion index;
Pre-HD = premanifest Huntington’s disease; ROI = region of inter-
est; SD = standard deviation; WM = white matter.
FIGURE 3: Neurite density index (NDI) correlations with clinical markers of disease progression. (A) Negative correlation
between NDI in the body of the corpus callosum and cumulative probability to onset (CPO). (B) Negative correlation between
NDI in the splenium of the corpus callosum and total motor score (TMS).
502 Volume 84, No. 4
ANNALS of Neurology
found that this correlation remained signiﬁcant
(r = −0.482, p = 0.0039).
In the current study, we have used a novel approach
to understand further the white matter microstructural
changes that underlie the macrostructural alterations previ-
ously identiﬁed in premanifest HD. By using NODDI,
we have examined tissue properties at the intra- and extra-
cellular level and have shown widespread reduction in axo-
nal density in pre-HD coupled with increased
organization in those areas most likely to be affected by
HD pathology. Furthermore, these ﬁndings are supported
both by an independent DTI analysis and the recent liter-
ature. We believe that here we present the most detailed
characterization of the effects of HD pathology on white
matter at the premanifest stage thus far achieved, and that
the role of axonal pathology and its mechanistic underpin-
nings could potentially be extended to other neurodegen-
erative disorders.
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